Biogen's anti-tau Alzheimer's drug misses Phase 2 goal, but claims signs of efficacy

Here we go again? Biogen reported heavily anticipated Alzheimer’s data on Thursday morning, saying its tau-targeting drug BIIB080 did not meet its primary endpoint in a Phase 2 study. But the company said it slowed ...